Direction of discordance between PET/CT, EBUS-TBNA, and multidisciplinary tumor board nodal assignment in non-small cell lung cancer

Mediastinal nodal classification in non–small cell lung cancer (NSCLC) at the N0/N1–N2/N3 treatment-defining boundary guides therapeutic strategy and is commonly finalized in multidisciplinary tumor board (MDT) meetings. We compared positron emission tomography/computed tomography (PET/CT) and endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) against MDT assignment and quantified discordance at this threshold. We retrospectively analyzed 114 consecutive NSCLC patients who underwent both PET/CT and EBUS-TBNA before MDT review. Nodal stage was dichotomized as N0/N1 vs N2/N3. Because the MDT decision incorporates both modalities, agreement with MDT is reported as observed agreement and Cohen κ together with the direction of discordance, rather than as sensitivity and specificity. In the subgroup with surgical mediastinal staging, both modalities and the MDT category were compared with histopathology. MDT assigned N2/N3 in 84 patients (73.7%). Relative to the MDT category, PET/CT over-classified 16 patients (14.0%) and under-classified 9 (7.9%). EBUS-TBNA under-classified 15 of the 43 patients it classified N0/N1 (34.9%), and under-classification persisted among the 25 patients in whom every sampled station was diagnostic (8/25, 32.0%); 12 of these 15 assignments rested on clinical–radiological course rather than histopathology. Agreement with the MDT category was 85.1% (κ = 0.662) for EBUS-TBNA and 78.1% (κ = 0.389) for PET/CT; because malignant cytology was definitional for the MDT category, 67 of 97 concordant EBUS-TBNA classifications (69.1%) were determined by that rule and do not measure EBUS-TBNA performance. Against surgical histopathology in 18 patients, PET/CT classified 11 of 13 pathologically N0 patients as N2/N3 (specificity 15.4%; 95% CI, 4.3–42.2) and EBUS-TBNA identified 2 of 5 with pathological N2 disease (sensitivity 40.0%; 95% CI, 11.8–76.9). At the treatment-defining nodal boundary, the two modalities diverged from the multidisciplinary decision in opposite directions: PET/CT over-classified nodal status, whereas EBUS-TBNA under-classified in approximately 1 in 3 patients it had assigned N0/N1, including those in whom sampling was complete, although most of these assignments rested on clinical course rather than tissue. These findings are consistent with guideline recommendations that PET-positive mediastinal nodes require tissue confirmation and that a negative endosonographic result be interpreted alongside pretest probability and station coverage.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-10-09
DOI
https://doi.org/10.1097/md.0000000000050981
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Direction of discordance between PET/CT, EBUS-TBNA, and multidisciplinary tumor board nodal assignment in non-small cell lung cancer

Ahmet Ursavaş, Orkun Eray Terzi, Ezgi Demirdöğen, Nilüfer Aylin Acet Öztürk et al.
Medicine
Lung Cancer Diagnosis and Treatment
article

Direction of discordance between PET/CT, EBUS-TBNA, and multidisciplinary tumor board nodal assignment in non-small cell lung cancer

Ahmet Ursavaş, Orkun Eray Terzi, Ezgi Demirdöğen, Nilüfer Aylin Acet Öztürk, Özge Aydin Güçlü
article en

Abstract

Mediastinal nodal classification in non–small cell lung cancer (NSCLC) at the N0/N1–N2/N3 treatment-defining boundary guides therapeutic strategy and is commonly finalized in multidisciplinary tumor board (MDT) meetings. We compared positron emission tomography/computed tomography (PET/CT) and endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) against MDT assignment and quantified discordance at this threshold. We retrospectively analyzed 114 consecutive NSCLC patients who underwent both PET/CT and EBUS-TBNA before MDT review. Nodal stage was dichotomized as N0/N1 vs N2/N3. Because the MDT decision incorporates both modalities, agreement with MDT is reported as observed agreement and Cohen κ together with the direction of discordance, rather than as sensitivity and specificity. In the subgroup with surgical mediastinal staging, both modalities and the MDT category were compared with histopathology. MDT assigned N2/N3 in 84 patients (73.7%). Relative to the MDT category, PET/CT over-classified 16 patients (14.0%) and under-classified 9 (7.9%). EBUS-TBNA under-classified 15 of the 43 patients it classified N0/N1 (34.9%), and under-classification persisted among the 25 patients in whom every sampled station was diagnostic (8/25, 32.0%); 12 of these 15 assignments rested on clinical–radiological course rather than histopathology. Agreement with the MDT category was 85.1% (κ = 0.662) for EBUS-TBNA and 78.1% (κ = 0.389) for PET/CT; because malignant cytology was definitional for the MDT category, 67 of 97 concordant EBUS-TBNA classifications (69.1%) were determined by that rule and do not measure EBUS-TBNA performance. Against surgical histopathology in 18 patients, PET/CT classified 11 of 13 pathologically N0 patients as N2/N3 (specificity 15.4%; 95% CI, 4.3–42.2) and EBUS-TBNA identified 2 of 5 with pathological N2 disease (sensitivity 40.0%; 95% CI, 11.8–76.9). At the treatment-defining nodal boundary, the two modalities diverged from the multidisciplinary decision in opposite directions: PET/CT over-classified nodal status, whereas EBUS-TBNA under-classified in approximately 1 in 3 patients it had assigned N0/N1, including those in whom sampling was complete, although most of these assignments rested on clinical course rather than tissue. These findings are consistent with guideline recommendations that PET-positive mediastinal nodes require tissue confirmation and that a negative endosonographic result be interpreted alongside pretest probability and station coverage.

MedicineVol. 105(41)
Bursa Uludağ Üni̇versi̇tesi̇ (TR), S.B.Ü. Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi (TR)
Openalex Percentile: Top 12%
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.